Invesco Nasdaq Biotechnology ETF (IBBQ) Dividend Yield, History & Forecast

Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund (ETF) listed on the NASDAQ Global Market. It pays a current dividend yield of 1.39% ($0.49 per share annually (TTM)). The most recent ex-dividend date was September 21, 2026, with payment scheduled for September 25, 2026. market capitalization is approximately $82M. Review IBBQ dividend history on this scorecard, compare peers in the Compare Dividend Returns tool, or project income with the dividend calculator.

IBBQ fund composition

IBBQ holds 248 positions, with 45.1% of assets in its ten largest. It charges an expense ratio of 0.19%, and manages $98.4M.

Top 10 holdings

HoldingWeight
AMGNAmgen Inc8.84%
VRTXVertex Pharmaceuticals Inc8.32%
GILDGilead Sciences Inc7.44%
REGNRegeneron Pharmaceuticals Inc5.60%
MRNAModerna Inc3.82%
RVMDRevolution Medicines Inc2.84%
ALNYAlnylam Pharmaceuticals Inc2.28%
BIIBBiogen Inc2.10%
ILMNIllumina Inc2.06%
ARGNFArgenx SE1.86%

Sector allocation

Healthcare99.9%Consumer Defensive0.2%Consumer Cyclical0.1%Financial Services0.1%Industrials0.0%Cash & Others0.0%

Frequently Asked Questions about Invesco Nasdaq Biotechnology ETF (IBBQ)

What is Invesco Nasdaq Biotechnology ETF's dividend yield?
Invesco Nasdaq Biotechnology ETF (IBBQ) pays a current trailing twelve-month dividend yield of 1.39%, which works out to $0.49 per share annually based on the most recent payout schedule.
When does Invesco Nasdaq Biotechnology ETF pay distributions?
The most recent ex-dividend date was September 21, 2026. The next scheduled dividend payment date is September 25, 2026.
How many years has Invesco Nasdaq Biotechnology ETF increased its dividend?
Invesco Nasdaq Biotechnology ETF (IBBQ) has increased its dividend for 3 consecutive years.
What does Invesco Nasdaq Biotechnology ETF invest in?
The Invesco Nasdaq Biotechnology ETF (IBBQ) seeks to mirror the investment performance of the Nasdaq Biotechnology Index. To achieve this, the Fund generally dedicates at least 90% of its total capital to the securities that make up this benchmark index. The underlying Index itself is specifically designed to gauge the returns of biotechnology and pharmaceutical companies whose shares are publicly traded on the Nasdaq Stock Market. Both the ETF and its corresponding Index undergo a yearly review and update of their composition each December, and their weightings are adjusted quarterly in...